<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445000</url>
  </required_header>
  <id_info>
    <org_study_id>ETOP 12-17</org_study_id>
    <secondary_id>2017-002063-17</secondary_id>
    <secondary_id>MO30176</secondary_id>
    <nct_id>NCT03445000</nct_id>
  </id_info>
  <brief_title>ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Treatment of Pretreated RET-rearranged Advanced NSCLC</brief_title>
  <acronym>ALERT-lung</acronym>
  <official_title>A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Thoracic Oncology Platform</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Thoracic Oncology Platform</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study to evaluate the activity of alectinib for the Treatment of pretreated
      patients with advanced NSCLC that have confirmed RETrearrangement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is investigating the efficacy of alectinib in patients with advanced stage
      RET-rearranged NSCLC, treated with at least one platinum based systemic chemotherapy regimen.
      Preclinical studies have shown that alectinib, a highly selective next generation ALK
      inhibitor, has potent anti-tumour activity in RET-rearranged NSCLC. Therapeutically, several
      multiple kinases inhibitors, are potentially able to inhibit RET kinase function, which has
      been tested in several unselected NCSLC trials. However, those result were negative and none
      of the tested drugs was approved for lung cancer treatment.

      The ALERT-lung trial is a single arm, phase II trial with the primary objective to assess the
      efficacy of alectinib in terms of best overall response (OR) assessed by RECIST v1.1 in
      selected NSCLC patients with RET rearrangement. The secondary objectives are to evaluate
      secondary measures of clinical efficacy including disease control, progression-free survival
      (PFS), and overall survival (OS) as well as to assess safety and tolerability of the
      treatment and to describe the association of primary and secondary outcomes with tumour
      characteristics.

      Alectinib is administered orally, 600 mg, twice per day, until progression, refusal or
      unacceptable toxicity. Trial treatment may also continue beyond progression, with physician
      and patient agreement, for as long as the patient may still derive clinical benefit. A total
      sample size of 44 patients is required.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best overall response</measure>
    <time_frame>From the start of trial treatment across all time points until the end of trial treatment, assssed up to 44 months.</time_frame>
    <description>Best overall response (OR = CR or PR), per investigator assessment according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response per independent review</measure>
    <time_frame>From the start of trial treatment across all time points until the end of trial treatment, assssed up to 44 months.</time_frame>
    <description>Best overall response (OR = CR or PR), per independent review assessment according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control at 24-weeks</measure>
    <time_frame>24 weeks after treatment start</time_frame>
    <description>Best overall response of CR or PR, or SD (or non-CR/non-PD in the case of non-measurable disease only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of enrolment until date of documented progression or death, if progression is not documented, assessed up to 44 months.</time_frame>
    <description>PFS will be assessed according to RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of enrolment until date of death from any cause, assessed up to 44 months.</time_frame>
    <description>Defined as the time from date of enrollment until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of alectinib treatment</measure>
    <time_frame>Assessed from date of signature of informed consent until 30 days after treatment is ceased for any reason.</time_frame>
    <description>The safety and tolerability of alectinib treatment will be assessed through analysis of the worst grade of toxicity/adverse events according to CTCAE v4.0 criteria observed over the whole treatment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>Non-small Cell Lung Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Trial treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity.
Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.
Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose.</description>
    <arm_group_label>Trial treatment</arm_group_label>
    <other_name>Alecensa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically documented non-small cell lung carcinoma

          2. Advanced disease defined as recurrent stage IV (according to 8th TNM classification)
             or recurrent or progressive disease following multimodal therapy (radiation therapy,
             surgical resection, or definitive chemo-radiation therapy for locally advanced
             disease)

          3. At least one prior platinum-based systemic regimen: Adjuvant or neoadjuvant or
             definitive platinum-based chemo-radiotherapy treatments are considered as a line of
             treatment only if completed less than 6 months before enrolment. Maintenance therapy
             following platinum doublet-based chemotherapy is not considered a separate regimen of
             therapy.

          4. RET rearrangement detected by FISH, Nanostring or by parallel-sequencing on FFPE
             tumour tissue assessed locally.

          5. Availability of FFPE tumour material for central confirmation of RETrearrangement

          6. Measurable or non-measurable, but radiologically evaluable (except for skin lesions)
             disease according to RECIST v1.1 criteria

          7. Age ≥18 years

          8. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

          9. Life expectancy &gt;3 months

         10. Adequate haematological function:

               -  Haemoglobin ≥9 g/dL

               -  Neutrophil count ≥1.5 ×109/L

               -  Platelet count ≥100 × 109/L

               -  WBC ≥2 ×109/L

         11. Adequate renal function: Calculated creatinine clearance ≥45 mL/min (according to
             Cockcroft-Gault formula)

         12. Adequate liver function:

               -  Total bilirubin ≤2x ULN (except patients with Gilbert Syndrome, who can have
                  total bilirubin ≤3.0 mg/dL)

               -  ALT and AST ≤3x ULN (≤5x ULN for patients with concurrent liver ¨ metastasis)

         13. Patient capable of proper therapeutic compliance, and accessible to correct followup.

         14. Women of childbearing potential, including women who had their last menstrual period
             in the last 2 years, must have a negative serum or urine beta HCG pregnancy test
             within 7 days before enrolment into the trial and within 3 days before alectinib
             treatment start.

         15. Sexually active men and women of childbearing potential must use an effective
             contraceptive method (intrauterine devices without hormones, bilateral tubal
             occlusion, vasectomized partner or total abstinence) during the trial treatment and
             for a period of at least 3 months following the last dose of alectinib.

         16. Recovered from any previous therapy related toxicity to Grade ≤1 at date of enrolment
             (except for recovery to Grade ≤2 of alopecia, fatigue, creatinine increased, lack of
             appetite or peripheral neuropathy)

         17. Written Informed Consent (IC) for trial treatment must be signed and dated by the
             patient and the investigator prior to any trial-related intervention.

        Exclusion Criteria:

          1. Untreated, active CNS metastases

          2. Carcinomatous meningitis

          3. Any previous (in the past 3 years) or concomitant malignancy EXCEPT adequately treated
             basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or
             bladder, in situ ductal carcinoma of the breast

          4. Any serious diseases or clinical conditions, including but not limited to uncontrolled
             active infection and any other serious underlying medical processes, that could affect
             the patient's capacity to participate in the trial

          5. Liver disease characterized by:

               -  ALT or AST &gt;3 × ULN (&gt;5 × ULN for patients with concurrent liver metastasis)
                  confirmed on two consecutive measurements or

               -  Impaired excretory function (e.g., hyperbilirubinaemia) or synthetic function or
                  other conditions of decompensated liver disease such as coagulopathy, hepatic
                  encephalopathy, hypoalbuminaemia, ascites, and bleeding from oesophageal varices
                  or

               -  Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis

          6. Patients with baseline symptomatic bradycardia

          7. Previous treatment with any RET TKI or RET targeted therapy.

          8. Any concurrent systemic anticancer therapy.

          9. Any GI disorder that may affect absorption of oral medications, such as malabsorption
             syndrome or status post major bowel resection.

         10. History of hypersensitivity to any of the additives in the alectinib drug formulation.

         11. Known HIV positivity or AIDS-related illness.

         12. Women who are pregnant or in the period of lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enriqueta Felip, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vall d'Hebron University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jürgen Wolf, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Cologne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Egbert F. Smith, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Ruepp, PharmD</last_name>
    <phone>+41315119416</phone>
    <email>regulatoryoffice@etop-eu.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unicancer - Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sophie Cousin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Greillier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Benjamin Besse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martin Faehling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martin Sebastian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jürgen Wolf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoracic Oncology Centre Munich</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Huber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. James Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sinead Cuffe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Instituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Domenico Galetta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Filippo de Marinis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Turin</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Silvia Novello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita di Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emilio Bria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Egbert Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne-Marie Dingemans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IPO Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Júlio Oliveira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Simona Borštnar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital general de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Santiago Viteri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ivana Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrara</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luis Paz Ares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manuel Cobo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HFR Fribourg</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Betticher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire de Genève</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alfredo Addeo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitatSpital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18(7):865-75. doi: 10.1634/theoncologist.2013-0095. Epub 2013 Jun 28. Review.</citation>
    <PMID>23814043</PMID>
  </results_reference>
  <results_reference>
    <citation>Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.</citation>
    <PMID>22327623</PMID>
  </results_reference>
  <results_reference>
    <citation>Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, Wanat AC, Stober LL, Digumarthy SR, Engelman JA, Shaw AT, Gainor JF. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 Nov;11(11):2027-2032. doi: 10.1016/j.jtho.2016.08.126. Epub 2016 Aug 17.</citation>
    <PMID>27544060</PMID>
  </results_reference>
  <results_reference>
    <citation>Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.</citation>
    <PMID>28447912</PMID>
  </results_reference>
  <results_reference>
    <citation>Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 2014 Dec;13(12):2910-8. doi: 10.1158/1535-7163.MCT-14-0274. Epub 2014 Oct 27.</citation>
    <PMID>25349307</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RET-rearrangement</keyword>
  <keyword>advanced NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

